Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.

@article{King2016GlycoproteinII,
  title={Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.},
  author={Shawn King and Marintha R. Short and Cassidy Harmon},
  journal={Vascular pharmacology},
  year={2016},
  volume={78},
  pages={10-6}
}
Glycoprotein (GP) IIb/IIIa inhibitors block platelet aggregation, reducing thrombotic events in acute coronary syndrome. They are most often utilized in patients who likely have an intracoronary thrombus. Tirofiban, eptifibatide, and abciximab are the three GP IIb/IIIa inhibitors approved for use in the United States. Each agent has unique pharmacological properties. They all have a rapid onset and are most often utilized in conjunction with heparin. Tirofiban, in particular, fell out of favor… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Platelet Integrin αIIbβ3 Inhibitor Rescues Progression of Apoptosis in Human Platelets

Medical science monitor : international medical journal of experimental and clinical research • 2016
View 3 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…